Hangzhou Jiuyuan Gene Engineering Valuation

Is 2566 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 2566 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 2566's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 2566's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 2566?

Key metric: As 2566 is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for 2566. This is calculated by dividing 2566's market cap by their current book value.
What is 2566's PB Ratio?
PB Ratio	n/a
Book	HK$0
Market Cap	HK$2.95b

2566 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	n/a
Enterprise Value/EBITDA	n/a
PEG Ratio	n/a

Price to Book Ratio vs Peers

How does 2566's PB Ratio compare to its peers?

The above table shows the PB ratio for 2566 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PB	Estimated Growth	Market Cap
Peer Average	1x
1477 Ocumension Therapeutics	1.4x	101.9%	HK$4.3b
2348 Dawnrays Pharmaceutical (Holdings)	0.5x	n/a	HK$1.8b
2633 Jacobson Pharma	0.7x	n/a	HK$1.6b
2161 JBM (Healthcare)	1.5x	n/a	HK$1.5b
2566 Hangzhou Jiuyuan Gene Engineering	n/a	n/a	HK$2.9b

Price-To-Book vs Peers: Insufficient data to calculate 2566's Price-To-Book Ratio vs. peers for valuation analysis.

Price to Book Ratio vs Industry

How does 2566's PB Ratio compare vs other companies in the HK Pharmaceuticals Industry?

1 Company	Price / Book	Estimated Growth	Market Cap

1 Company		Estimated Growth	Market Cap

No more companies

Price-To-Book vs Industry: Insufficient data to calculate 2566's Price-To-Book Ratio vs. industry for valuation analysis.

Price to Book Ratio vs Fair Ratio

What is 2566's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

2566 PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio	n/a
Fair PB Ratio	n/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate 2566's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

3SBio

HK$13.5b

An investment holding company, develops, produces markets, and sells biopharmaceutical products in Mainland China and internationally.

1530

HK$5.72

-2.2%

-22.2%

China Shineway Pharmaceutical Group

HK$6.6b

An investment holding company, engages in the research and development, manufacture, and trade of Chinese medicines in the People’s Republic of China and Hong Kong.

2877

HK$8.76

5.8%

n/a

United Laboratories International Holdings

HK$18.9b

An investment holding company, engages in the research and development, manufacture, distribution, and sale of pharmaceutical products.

3933

HK$10.42

3.6%

31.9%